By Signing up for our emails, you'll be the first to receive the best discounts InVite Health has to offer.
Reishi Mushroom extract was screened for its anti-proliferative activity using 26 human cancer cell
lines. It was found that Reishi Mushroom inhibited the life cycle of the cancer cells especially
right before or during there division into new cancer cells. In checking for the ability to kill
the cancer cells it was found that Reishi caused the destruction of the myeloma (U937 cells,
RPM18226 cells), leukemia (HL-60), and lymphoma (Blin-1 cells) cells assessed for this from 21% to
92%. The research was performed at the David Geffen School of Medicine at UCLA, Los Angeles, and
the Division of Hematology-Oncology, University Hospital, Freiburg, Germany, and appears in the
January 16th, 2006 issue of the journal Leukemia Research.
Commentary by Jerry Hickey, R.Ph.
Hopefully none of us will encounter an agent as destructive as mustard gas, but it is good for us
to note that these particular antioxidants are very lung friendly and that available oral supplement
levels have shown protective activity in research.
Resveratrol may fight multiple myeloma and other B cell malignancies
Resveratrol has potent cancer preventing effects against various tumors and it is the
Trans-Resveratrol isomer that has all the anticancer activity. In order for cancer cells to
duplicate themselves and go through their rapid multiplication they must go through the cell
cycle where they create copies of themselves. In this study it was found that Resveratrol rapidly
causes human cancerous B cells including myeloma cells to stop their cell cycle at the S-phase.
This is very important - the S-phase is when DNA (genetic material) is copied. The greater the
concentration of Resveratrol and the longer the exposure, the better the results. Resveratrol
killed the cancer cells by stimulating Caspase-3 activity; this is a cellular executioner that
can slaughter cancer cells. These results suggest that Resveratrol has a potential place in patients
with B cell cancers including multiple myeloma. The study was performed at the Division of
Hematology, Keio University School of Medicine, Tokyo, Japan, and is published in the January 18th,
2006 issue of the journal Biochemical Pharmacology.